^
Association details:
Biomarker:MAP2K2 mutation
Cancer:Melanoma
Drug Class:CTLA4 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma

Published date:
01/04/2022
Excerpt:
Compared to patients with wild-type MAP2K1/2, those with MAP2K1/2 mutations in an independent anti-CTLA-4-treated cohort had higher objective response rates, longer progression-free survival, and longer overall survival (OS). These findings were further validated in a pooled anti-CTLA-4-treated cohort in terms of the OS.
DOI:
10.3389/fimmu.2021.785526
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

The predictive value of MAP2K1/2 mutations for efficiency of immunotherapy in melanoma

Published date:
05/19/2021
Excerpt:
In an independent anti-CTLA-4-treated cohort (n = 110), we found that MAP2K1/2 mutations are predictive of high objective response rate (17.6% vs 1.3%, p = 0.0185) and long progression-free survival...identified mutations in MAP2K1/2 genes as the independent predictive factors for anti-CTLA-4 therapy in melanoma patients and found that anti-CTLA-4 treatment in patient harbouring MAP2K1/2 mutations might be more effective than the anti-PD-1 therapy.
DOI:
10.1200/JCO.2021.39.15_suppl.e21587